Darae战略事业化中心 Co., Ltd. (CEOs Bae Sun-gu and Kim Jeong-guk), a leading expert in 技术特例上市 consulting, and RudaCure Inc. (CEO Yongho Kim), a drug developer targeting 感觉障碍 diseases, have solidified their strategic partnership.
On the 4th, the two companies signed an 'MOU for IP Portfolio Strategy Development and Technology-Based Listing Evaluation Consulting for RudaCure Inc.'
Through this MOU and investment, Darae战略事业化中心 will provide comprehensive consulting to RudaCure Inc.—which is planning a 技术特例上市—including mock evaluations for 技术特例上市, IP portfolio and R&D strategy, and investment support, in order to help RudaCure Inc. successfully achieve a stable 技术特例上市 with its excellent technologies and drugs.
Darae战略事业化中心 holds the highest reputation in the 制药 and bio consulting industry, consulting dozens of 制药 and bio companies each year. It provides a wide range of consulting services including 技术特例上市 consulting, IP consulting, R&D strategy, and technology valuation, and is also actively involved as an accelerator and investor. Recently, the company has been concentrating its capabilities on 技术特例上市 consulting for 制药 and bio companies.
RudaCure Inc. has already had licensing experience with 干眼症治疗药s and 角膜损伤 treatments in 2021 and 2023, and is currently developing a best-in-class powerful 非麻醉性镇痛药. The company is developing 创新药物s for various intractable diseases targeting GTPase and 离子通道s, and is actively conducting research on 银屑病, 特应性皮炎, and anticancer agents. As a 生物风投企业 pursuing continuous growth through 联合研究 and 联合开发 with 国内外 制药公司, RudaCure is well-positioned for future expansion.
RudaCure Inc. CEO Yongho Kim said, "Through substantive mutual cooperation with Darae战略事业化中心, with whom we have built a relationship over the past three years, we will grow into a 生物风投企业 with even stronger 知识产权 and differentiated technologies going forward," expressing expectations for the strategic collaboration.
RudaCure Inc. is currently identifying compounds effective for chemotherapy-induced and cancer-related pain, and is preparing to present the technology at the 2023 ASCO conference. As a member of the 临床试验 delegation, the company plans to simultaneously engage in exchange and technology promotion regarding anticancer 临床试验 on-site.
Yakup Sinmun: RudaCure "Formally begins preparations for technology-based IPO listing"